Tankyrase Inhibitor for Cardiac Tissue Regeneration: an In-silico Approach

Document Type : Research article


1 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

2 Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.



Myocardial infarction causes heart tissue damages; therefore, using non-invasive methods to regenerate the heart tissue could be very helpful. Recent studies claimed that the inhibition of the Wnt signaling could promote cardiac remodeling and induce cardiac regeneration. Therefore, a tankyrase inhibitor to stabilize the AXIN and inhibit the Wnt/β-catenin signaling pathway will induce cardiac regeneration after injury. In this regard, virtual screening procedure, using molecular docking of 9127 FDA and world approved drugs, including herbal medicine, was done over the crystal structures of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) catalytic poly (ADP-ribose) polymerase (PARP) domains with PDB ID: 2RF5 and 3KR7, respectively, to find potential small molecule inhibitors to regenerate injured heart tissue. Subsequently, molecular dynamics simulations were done to assess the stability of selected ligands phenothrin and ethyl rosinate in the binding pocket of TNKS1 and TNKS2 for 100 ns, respectively. Both compounds show suitable interaction in their binding pocket. The molecular dynamics simulation results confirm their stability. The binding free energy of complexes was carried out by the MM-PBSA method. ADME properties also indicate the potential of drug-likeness of both compounds. Taking together both drugs may be promising for inducing cardiac regeneration after injury. Nevertheless, clinical approval remains. 

Graphical Abstract

Tankyrase Inhibitor for Cardiac Tissue Regeneration: an In-silico Approach


 (1) Quaife-Ryan GA, Sim CB, Ziemann M, Kaspi A,
Rafehi H, Ramialison M, El-Osta A, Hudson J and
Porrello ER. Multicellular Transcriptional Analysis
of Mammalian Heart Regeneration. Circulation
(2017) 136: 1123-39.
(2) Reyes EB, Ha JW, Firdaus I, Ghazi AM,
Phrommintikul A, Sim D, Vu QN, Siu CW, YinWH
and Cowie MR. Heart failure across Asia: Same
healthcare burden but differences in organization
of care. Int. J. Cardiol. (2016) 223: 163-7.
(3) Bassat E, Mutlak YE, Genzelinakh A, Shadrin IY,
Baruch Umansky K, Yifa O, Kain D, Rajchman
D, Leach J, Bassat DR, Udi Y, Sarig R, Sagi I,
Martin JF, Barsac N, Cohen S and Tzahor E. The
extracellular matrix protein agrin promotes heart
regeneration in mice. Nature (2017) 547: 179-84.
(4) Krafts KP. Tissue repair: The hidden drama.
Organogenesis (2010) 6: 225-33.
(5) Reya T, Duncan AW, Ailles L, Domen J, Scherer
DC, Willert K, Hintz L, Nusse R and Weissman
IL. A role for Wnt signalling in self-renewal of
haematopoietic stem cells. Nature (2003) 423: 409-
(6) MacDonald BT, Tamai K and He X. Wnt/betacatenin signaling: components, mechanisms, and
diseases. Dev. Cell (2009) 17: 9-26.
(7) Clevers H. Wnt/beta-catenin signaling in
development and disease. Cell (2006) 127: 469-80.
(8) Komiya Y and Habas R. Wnt signal transduction
pathways. Organogenesis (2008) 4: 68-75.
(9) Kuhl M, Sheldahl LC, Park M, Miller JR and Moon
RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt
signaling pathway takes shape. Trends Genet.
(2000) 16: 279-83.
(10) Fearon ER. PARsing the phrase “all in for Axin”-
Wnt pathway targets in cancer. Cancer Cell (2009)
16: 366-8.
(11) Waaler J, Machon O, Tumova L, Dinh H, Korinek
V, Wilson SR, Paulsen JE, Pedersen NM, Eide
TJ, Machonova O, Gradle D, Voronkon. A novel
tankyrase inhibitor decreases canonical Wnt
signaling in colon carcinoma cells and reduces
tumor growth in conditional APC mutant mice.
Cancer Res. (2012) 72: 2822-32.
(12) Gessert S and Kuhl M. The multiple phases and
faces of wnt signaling during cardiac differentiation
and development. Circ. Res. (2010) 107: 186-99.
(13) Hermans KC, Daskalopoulos EP and Blankesteijn
WM. Interventions in Wnt signaling as a novel
therapeutic approach to improve myocardial infarct
healing. Fibrogenesis Tissue Repair (2012) 5: 16.
(14) Saraswati S, Alfaro MP, Thorne CA, Atkinson J,
Lee E and Young PP. Pyrvinium, a potent small
molecule Wnt inhibitor, promotes wound repair
and post-MI cardiac remodeling. PLoS One (2010)
5: 15521.
(15) Laeremans H, Hackeng TM, van Zandvoort MA,
Thijssen VL, Janssen BJ, Ottenheijm HC, Smits
JF and Blankestejin WM. Blocking of frizzled
signaling with a homologous peptide fragment
of wnt3a/wnt5a reduces infarct expansion and
prevents the development of heart failure after
myocardial infarction. Circulation (2011) 124:
(16) Yang D, Fu W, Li L, Xia X, Liao Q, Yue R, Chen H,
Chen X, An S, Zeng C and Wang WE. Therapeutic
effect of a novel Wnt pathway inhibitor on cardiac
regeneration after myocardial infarction. Clin. Sci.
(2017) 131: 2919-32.
(17) Ng LF, Kaur P, Bunnag N, Suresh J, Sung ICH, Tan
QH, Gruber J and Tolwinski NS. WNT Signaling in
Disease. Cells (2019) 8: 826.
(18) Verma A, Kumar A, Chugh A, Kumar S and Kumar
P. Tankyrase inhibitors: emerging and promising
therapeutics for cancer treatment. Med. Chem. Res.
(2021) 30: 50-73.
(19) Almasoud N, Binhamdan S, Younis G, Alaskar H,
Alotaibi A, Manikandan M, Alfayez M, Kassem M
and AlMurakhini N. Tankyrase inhibitor XAV-939
enhances osteoblastogenesis and mineralization
of human skeletal (mesenchymal) stem cells. Sci.
Rep. (2020) 10: 16746.
(20) Lakshmi TV, Bale S, Khurana A and Godugu C.
Tankyrase as a novel molecular target in cancer
and fibrotic diseases. Curr. Drug Targets (2017)
18: 1214-24.
(21) Chovancova E, Pavelka A, Benes P, Strnad O,
Brezovsky J, Kozlikova B, Gora A, Sustr V,
Klvana M, Medek P, Biedermannova L, Sochor
J and Damborsky J. CAVER 3.0: a tool for the
analysis of transport pathways in dynamic protein
structures. PLoS Comput. Biol. (2012) 8: 1002708.
(22) Samdani A and Vetrivel U. POAP: A GNU parallel
based multithreaded pipeline of open babel and
AutoDock suite for boosted high throughput virtual
screening. Comput. Biol. Chem. (2018) 74: 39-48.
(23) Santos-Martins D, Forli S, Ramos MJ and Olson
AJ. AutoDock4(Zn): an improved AutoDock
force field for small-molecule docking to zinc
Hosseini F S et al. / IJPR (2021), 20 (4): 315-328
metalloproteins. J Chem Inf Model. (2014) 54:
(24) Novick PA, Ortiz OF, Poelman J, Abdulhay AY and
Pande VS. SWEETLEAD: an in-silico database of
approved drugs, regulated chemicals, and herbal
isolates for computer-aided drug discovery. PLoS
One (2013) 8: 79568.
(25) BIOVIA DS. Discovery studio modeling
environment. : San Diego: Dassault Systèmes;
(26) The PyMOL Molecular Graphics System. Version
1.1evel: Schrödinger, LLC. Available from: URL:
https://pymol.org; (2017).
(27) Vanommeslaeghe K, Hatcher E, Acharya C, Kundu
S, Zhong S, Shim J, Darian E, Guvench O, Lopes P,
Vorobyov I and Mackerell AD. CHARMM general
force field: A force field for drug-like molecules
compatible with the CHARMM all-atom additive
biological force fields. J. Comput. Chem. (2010)
31: 671-90.
(28) Kumari R, Kumar R, Open Source Drug Discovery
C, Lynn A. g_mmpbsa--a GROMACS tool for
high-throughput MM-PBSA calculations. J. Chem.
Inf. Model (2014) 54: 1951-62.
(29) Salic A, Lee E, Mayer L and Kirschner MW.
Control of beta-catenin stability: reconstitution
of the cytoplasmic steps of the wnt pathway in
Xenopus egg extracts. Mol. Cell (2000) 5: 523-32.
(30) Ferri M, Liscio P, Carotti A, Asciutti S, Sardella
R, Macchiarulo A and Camaioni E. Targeting
Wnt-driven cancers: Discovery of novel tankyrase
inhibitors. Eur. J. Med. Chem. (2017) 142: 506-22.
(31) Li J, Mahajan A and Tsai MD. Ankyrin repeat:
a unique motif mediating protein-protein
interactions. Biochem. (2006) 45: 15168-78.
(32) De Rycker M and Price CM. Tankyrase
polymerization is controlled by its sterile alpha
motif and poly(ADP-ribose) polymerase domains.
Mol. Cell. Biol. (2004) 24: 9802-12.
(33) Haikarainen T, Krauss S and Lehtio L. Tankyrases:
structure, function and therapeutic implications in
cancer. Curr. Pharm. Des. (2014) 20: 6472-88.
(34) Hosseini FS and Amanlou M. Anti-HCV and antimalaria agent, potential candidates to repurpose for
coronavirus infection: Virtual screening, molecular
docking, and molecular dynamics simulation study.
Life Sci. (2020) 258: 118205.
(35) Damale MG, Patil R, Ansari SA, Alkahtani
HM, Almehizia AA, Pathan SK, Chhajed S and
Sangshetti J. Identification of dual site inhibitors
of tankyrase through virtual screening of proteinligand interaction fingerprint (PLIF)–derived
pharmacophore models, molecular dynamics, and
ADMET studies. Struct. Chem. (2020) 31: 769-79.
(36) Daina A, Michielin O and Zoete V. SwissADME: a
free web tool to evaluate pharmacokinetics, druglikeness and medicinal chemistry friendliness of
small molecules. Sci Rep. (2017) 7: 42717.
(37) Benet LZ, Hosey CM, Ursu O and Oprea TI.
BDDCS, the Rule of 5 and drugability. Adv. Drug
Deliv. Rev. (2016) 101: 89-98.
(38) Narwal M, Koivunen J, Haikarainen T, Obaji
E, Legala OE, Venkannagari H, Joensuu P,
Pihlajaniemi T and Lehtio L. Discovery of
tankyrase inhibiting flavones with increased
potency and isoenzyme selectivity. J. Med. Chem.
(2013) 56: 7880-9.
(39) Damale MG, Pathan SK, Shinde DB, Patil RH,
Arote RB and Sangshetti JN. Insights of tankyrases:
A novel target for drug discovery. Eur. J. Med.
Chem. (2020) 207: 112712.
(40) James RG, Davidson KC, Bosch KA, Biechele
TL, Robin NC, Taylor RJ, Major MB, Camp ND,
Fowler K, Martins TJ and Moon RT. WIKI4, a
novel inhibitor of tankyrase and Wnt/ss-catenin
signaling. PLoS One (2012) 7: 50457.
(41) Shultz MD, Kirby CA, Stams T, Chin DN, Blank
J, Charlat O, Cheng H, Cheung A, Cong F, Feng
Y, Fortin PD, Hood T, Tyagi V, Xu M, Zhang B
and Shao W. [1,2,4]triazol-3-ylsulfanylmethyl)-3-
phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt
pathway that inhibit tankyrases 1 and 2 via novel
adenosine pocket binding. J. Med. Chem. (2012)
55: 1127-36.